Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
Journal Article
|Research
2023-04-28 • PLOS Global Public Health
2023-04-28 • PLOS Global Public Health
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...
Journal Article
|Research
2022-11-10 • PLOS One
2022-11-10 • PLOS One
BACKGROUND
Journal Article
|Review
2016-05-25 • PLOS One
2016-05-25 • PLOS One
INTRODUCTION
There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains li...
There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains li...
Journal Article
|Research
2022-02-01 • International Journal of Tuberculosis and Lung Disease
2022-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Journal Article
|Research
2016-03-01 • International Journal of Tuberculosis and Lung Disease
2016-03-01 • International Journal of Tuberculosis and Lung Disease
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new dru...
Journal Article
|Research
2016-09-01 • European Respiratory Journal
2016-09-01 • European Respiratory Journal
Debate persists about monitoring method (culture or smear) and interval (monthly or less frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing ...